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Opium Alkaloids
Mahluga Jafarova Demirkapu and Hasan Raci Yananli
Abstract
Opium alkaloids, derived from crude Papaver somniferum L. plant, are potent
analgesic drugs, but their use is limited because of dependence and withdrawal.
Opium alkaloids activate the mesocorticolimbic dopaminergic system, which pro-
ject from the ventral tegmental area to the nucleus accumbens and medial prefron-
tal cortex, and dopamine is critically important in opioid consumption and
sustaining. The reward effect resulting from the activation of the dopaminergic
system leads to continued opioid consumption and occurs opioid dependence. After
the development of opioid dependence, consumption continues to avoid with-
drawal syndrome. Opioid dependence is accompanied with tolerance, which
requires the use of high doses to achieve the same effect. When tolerance develops,
the chronic consumer continues to use opioid above known toxic doses to produce
the same effect, which can result in death regardless of the type of opioid used. Raw
Papaver somniferum L. has five high-density main opium alkaloids including mor-
phine, noscapine, codeine, thebaine, and papaverine. Some of these alkaloids bind
to classical opioid receptors to produce an opioid-like effect, while the other part
mediates non-opioid effects. This chapter reviews the opiod history, receptors,
mechanism of action, dependence, withdrawal. In addition, general information
about five main opium alkaloids, their effects, uses, routes of administration, phar-
macokinetics, adverse reactions, contraindications; effects on reproduction, preg-
nancy, and lactation were compiled.
Keywords: morphine, noscapine, codeine, thebaine, papaverine
1. Introduction
Opium alkaloids are products obtained from the mature capsules of Papaver
somniferum L. plant in natural way or in laboratory. Although the maintenance of
Papaver somniferum L. is very easy, obtaining opium alkaloids naturally requires a
process. Maturation of capsules occurs in May or June. First, the mature capsules are
incised several times to allow the latex to flow. The exposed white latex turns brown
with the effect of air. The thickened and solidified latex is collected the next day,
dried under suitable conditions and made ready for use [1]. The natural way of
extracting opium alkaloids for medical purposes is dried capsules [2]. The main
opium alkaloids found in raw Papaver somniferum L. and some information are
summarized in Table 1.
1.1 History
Papaver somniferum L. is one of the oldest medicinal plants. The first information
about the production of opium alkaloids is found on Sumerian clay tablets inscribed
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in Cuneiform script in about 3000 BC. The Sumerians, whose culture developed
between the Tigris and Euphrates Rivers in the south of Iraq between 4000 and
3000 BC, called the opium alkaloids “Gil“ (“happiness”) [4].
Opium alkaloids were first isolated in 1803 by Parisian Derosne, and named
‘opium salt’. Friedrich Wilhem Adam Serturner described the ‘opium salt’ in detail
in 1817 and named “morphine', inspired by the Morpheus (Greek god of dreams).
Karl Friedrich Wilhelm Meissner first used the word ‘alkaloid’ in 1818, which we
still use. Opioids were widely used for the first time in the Franco-Prussian War and
the American Civil War for medical purposes. Tincture and pills were preferred for
the purpose of analgesia in wounded soldiers. Repeated use caused opioid depen-
dence on some soldiers, and this event was first described as “soldiers’ disease” [5].
1.2 Opioid receptors
Although morphine and other opioid alkaloids are exogenous substances, they
show agonistic effect by binding to the receptors of endogenous opioids. Opioid
receptors were first described by Beckett and Casy in 1954 [6]. In 1965, Portoghese
and colleagues shared their views on the existence of multiple opioid receptor types
[7]. High-affinity and stereospecific binding sites for opioid alkaloids were also
found in brain in 1973 [8]. The presence of specific opioid receptors led to the
discovery of endogenous ligands. They are enkephalins [9], β-endorphin [10], and
dynorphins [11]. The classic opioid receptors, were discovered in 1976–1977 and
named after the prototypic drugs or tissue used in these studies: μ (mu, for mor-
phine), δ (delta, for deferens), and κ (kappa, for ketocyclazocine) [12, 13]. These
receptors show seven transmembrane domain structures specific to G protein-
coupled receptors, are induced by morphine and antagonized by naloxone, and had
similar analgesic effect. In 1995, the fourth opioid receptor, which is similar in
structure with and closely related to classic opioid receptors, was also discovered
[14, 15]. Fourth opioid receptor initially identified as ORL1 or LY132, it was later
updated to N/OFQ by taking the name of its endogenous ligands (nociceptin/
orphanin FQ) [16]. Although the effects of N/OFQ receptor are not fully known,
they do not have a similar effect on pain as classical opioid receptors, and their
sensitivity to naloxone is very low. σ (sigma), ε (epsilon), and ζ (zeta) receptors and
λ (lambda) site are included in other opioid receptors [17]. The σ receptor, discov-
ered in 1976, is not coupled to G protein, and its effects are not antagonized by
naloxone [12, 18, 19]. The ε receptor is sensitive to β-endorphin [20]. The λ site
regulates cell growth and is not antagonized by naloxone [21, 22]. Further informa-
tion on opioid receptors is summarized in Table 2.
According to the studies, μ receptor was also related with addiction [38], modu-
lation of dopaminergic system [39], learning and memory [40]. The δ receptors
along with μ receptors contribute to emotional sensitivity [41].
Density (avg%) [3] Molecular formula Molecular weight (g/mol)
Morphine 11.4 C17H19NO3 285.34
Noscapine 8.1 C22H23NO7 413.4
Codeine 3.5 C18H21NO3 299.4
Thebaine 3.2 C19H21NO3 311.4
Papaverine 3.1 C20H21NO4 339.4
Table 1.
The main opium alkaloids found in crude Papaver somniferum L. and some information.
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Opioid receptors μ receptor δ receptor κ receptor N/OFQ receptor
Other names OP3, MOP, MOPr,
Mu 1
OP1, DOP,
DOR, DOPr,
DOR-1
OP2, KOP,
KOPr, KOR-1
OP4, KOR-3, NOCIR,
kappa3-related,
MOR-C, nociceptin
receptor ORL, XOR1,
NOP-r, nociceptin/
orphanin FQ, NOPr
Regions
with high
distribution
CNS Thalamus
Caudate putamen
Neocortex
Nucleus accumbens
(NAc)
Amygdala
İnterpeduncular
complex
İnferior and
superior colliculi
[23]
Olfactory bulb
Neocortex
Caudate
putamen
NAc
Amygdala [23]
Cerebral cortex
NAc
Claustrum
Hypothalamus
[23, 24]
Cerebral cortex
Anterior olfactory
nucleus
Lateral septum
Ventral forebrain
Hippocampus
Hypothalamus
Amygdala
Substantia nigra
Ventral tegmental area
(VTA)
Locus coeruleus
Brain stem nuclei [25]
Spinal
cord
Superficial layers dorsal horn of spinal cord [26] Dorsal horn [25]
Non-
CNS
Skin [27]
Immune cells [29]
Pregnant uterus [31]
Gastrointestinal
(GI) tract [32]
Cochleae [34]
Skin [28]
Immune
cells [30]
Pregnant
uterus [31]
GI tract [33]
Cochleae [34]
Skin[28]
Immune
cells [30]
Pregnant
uterus [31]
GI tract [33]
Cochleae [34]
Types of G-protein Primary: Gi/Go
Secondary: Gq/G11
Gi/Go Primary: Gi/Go
Secondary: G12/
G13
Primary: Gi/Go
Endogenous ligands β-endorphin
Enkephalins
Endomorphin-1 and
-2
β-endorphin
Enkephalins
Dynorphin A
Dynorphin B
α-neoendorphin
Nociceptin
Orphanin FQ
Agonists [from
main opium
alkaloids]
Morphine
Codeine
Morphine Morphine
Antagonists Naloxone
Naltrexone
Naloxone
Naltrexone
Naloxone
Naltrexone
[Nphe1]N/OFQ-
(1-13)-NH2
UFP-101
Effects Analgesia
Respiratory
functions
Cardiovascular
functions
GI motility
Neuroendocrine
functions
Immune system
functions
Feeding
Mood
Thermoregulation
[35]
Analgesia [36]
Cardiovascular
functions
GI motility
Mood
Behaviour [15]
Analgesia
Neuroendocrine
functions
Immune system
functions
Diuresis
Feeding [35]
Nociception
Motor and aggressive
behaviours
Reinforcement and
reward
Stress response
Autonomic system
functions
Immune system
functions [37]
Table 2.
Opioid receptors and their properties.
3
Opium Alkaloids
DOI: http://dx.doi.org/10.5772/intechopen.91326
1.3 Mechanism of action
μ, δ, and κ opioid receptors are distributed in peripheral tissue as well as CNS.
Stimulation of these receptors in the CNS results in analgesia, drowsiness, euphoria,
a sense of detachment, respiratory depression, nausea and vomiting, depressed
cough reflex, and hypothermia. When these receptors are stimulated in peripheral
tissues, miosis, orthostatic hypotension, constipation, urinary retention etc.
emerges.
After stimulation of these Gi/0-coupled opioid receptors, the adenylate cyclase
enzyme is suppressed and the level of cyclic AMP decreases. In addition, the
voltage-gated calcium channels in the axon ends or neuron soma are closed and
intracellular calcium levels are reduced, potassium channels are opened and leading
to an increase in potassium conductance. As a result, inhibition and hyperpolariza-
tion of neurons occurs when opioid receptors are stimulated [42, 43].
Analgesic or antinociceptive effects, which are indicated for use of opioids,
develop at the level of the brain and spinal cord. At the brain level, attenuation of
impulse spread is weakened and the perception of pain is inhibited, and at the spinal
cord level, the transmission of pain impulses is suppressed [44].
1.4 Opioid dependence
Opioid dependence or addiction is a chronic, recurrent disease that changes
neurotransmitter systems in the CNS and affects movement [45, 46]. Opioid
dependence develops in both psychic and physical dependence. Physical opioid
dependence occurs both when used for treatment and as a result of abuse. Opioid
abuse is a relapsing disease with high morbidity and mortality, which is used at
higher doses to produce the same effect due to tolerance. The higher the exposure
time to opioids, the higher the degree of dependence and tolerance. After physical
dependence develops, opioid consumption is maintained to prevent withdrawal
symptoms. So the treatment is long and difficult. For this purpose, opioid agonists
such as methadone, buprenorphine, an opioid antagonist naltrexone or abstinence-
based treatment may be preferred. This disease, referred to as ‘opioid abuse and
opioid dependence’ in the Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision (DSMIV-TR), has been changed to ‘opioid use disor-
der’ in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
(DSM-5) [47].
The estimated annual prevalence of opioids in 2010 was 0.6–0.8% of the popu-
lation aged 15–64 (26  106 to 36  106). The estimated annual prevalence of opioid
use is between 0.3 and 0.5% of the adult population (13  106 to 21  106 past-year
users) [48].
The mesocorticolimbic dopaminergic system, which project from the VTA to the
NAc and medial prefrontal cortex (mPFC) are critically important in opioid depen-
dence [49]. Opioids act on VTA and directly or indirectly cause an increase in
dopamine release in NAc region [50]. In the pathogenesis of opioid dependence, the
presence of a complex mechanism including the dopaminergic system, noradrener-
gic, serotonergic, etc. systems should be considered [51].
1.5 Opioid withdrawal
Withdrawal is a condition that occurs when the use of an exogenous substance
that is used for a long time and develops physical dependence is interrupted. In
opioid dependence, the mesocorticolimbic dopaminergic system activates and
induces dopamine release in the NAc region. The adaptive increase in dopaminergic
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activity in CNS in opioid dependence is suppressed during withdrawal and with-
drawal symptoms appear [52]. In addition to dopamine, different neurotransmitters
and neuromodulators, such as noradrenaline, GABA, vasopressin, substance P,
neuropeptide Y, and nitric oxide, are thought to play a role in the development of
opioid withdrawal [53–55]. In opioid withdrawal syndrome, symptoms such as pain,
insomnia, yawning, tremor, lacrimation, rhinorrhea, sweating, dehydration,
goosebumps, mydriasis, restlessness, anorexia, nausea, vomiting, diarrhea, weight
loss, hyperglycemia, hypotension, decrease in respiratory rate, hyperthermia and
abdominal muscle cramps are seen [45].
2. The main opium alkaloids in raw Papaver somniferum L. and their
pharmacological properties
2.1 Morphine
International Union of Pure and Applied Chemistry (IUPAC) name:
(4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-
methanobenzofuro[3,2-e]isoquinoline-7,9-diol.
ATC
Code
N-Nervous
system
N02-
Analgesics
N02A-
Opioids
N02AA-Natural opium
alkaloids
N02AA01-
Morphine
Morphine is one of the major opium alkaloids isolated from plant Papaver
somniferum L., produced synthetically and metabolized by codeine and heroin in the
body. It binds to μ, δ, and κ receptors, which are widely distributed in CNS and
peripheral tissue, and produce effects such as analgesia, anxiolysis, euphoria, seda-
tion, respiratory depression, and contraction of smooth muscles of GI tract. Mor-
phine is used in the management of severe pain, treatment of acute pulmonary
edema and anesthetic procedures [56]. It can be administered orally, rectally, intra-
muscularly, intravenously, subcutaneously, epidurally, and intrathecally.
Absorption of morphine is variable, an almost complete absorption mainly done
in the upper intestine as well as in the rectal mucosa. Morphine presents significant
first-pass metabolism and oral bioavailability within 17–33% [57]. Morphine dis-
tributes to brain, skeletal muscle, liver, kidneys, lungs, intestinal tract, and spleen
[58]. Hepatic metabolism occurs via glucuronic acid conjugation primarily to mor-
phine-6-glucuronide (M6G, 10–15%) and morphine-3-glucuronide (M3G, 45–55%).
Other metabolites include morphine-3,6-diglucuronide, morphine-3-ethereal sul-
phate, normorphine, normorphine-6-glucuronide, normorphine-3-glucuronide and
codeine. M6G and normorphine show active analgesic effect by binding to opioid
receptors, but M6G, which is formed more than normorphine, can contribute to
analgesic effect of morphine. M3G does not contribute to the analgesic effect of
morphine, because it has low affinity to opioid receptors [59]. Half-life elimination
is variable according to age group: in neonates 4.5–13.3 h, in children 1–2 h, and in
adults 2–4 h. Excretion occurs with urine (2–12%) and feces (7–10%).
Morphine leads to death in amounts of 0.15–0.2 g (sc) or 0.3–0.4 g (oral) in
adults. Babies and young children are much more susceptible, and death has
been observed at doses of 30 mg [60]. Morphine blood concentration within
10–100 μg/dL is toxically; if it is above 400 μg/dL is lethally [61].
Common adverse reactions are drowsiness, headache, constipation, nausea,
vomiting, urinary retention. Although less common adverse reactions, such as
depression, insomnia, paresthesia, dizziness, anxiety, abnormal dreams, confusion,
seizure, myoclonus, agitation, amnesia, euphoria, pain, dyspnea, hypoventilation,
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respiratory depression, tremor, fever, flu-like symptoms, rhinitis, edema, hypoten-
sion, syncope, palpitations, skin rash, amblyopia, blurred vision, conjunctivitis,
diplopia, miosis, nystagmus, amenorrhea, impotence, gynecomastia, urinary hesi-
tancy, diaphoresis, anorexia, biliary colic, dyspepsia, gastroesophageal reflux dis-
ease, hiccups, xerostomia, anemia, thrombocytopenia can be seen.
Contraindications are hypersensitivity to morphine, significant respiratory
depression, acute or severe bronchial asthma in the absence of resuscitative equip-
ment, GI obstruction.
Effects on reproduction: Prolonged morphine use can cause secondary
hypogonadism, which can lead to infertility in both sexes [62].
Effects on pregnancy: It is known that, morphine crosses the placenta. Morphine
exposure was associated with conoventricular septal defects, atrioventricular septal
defects, hypoplastic left heart syndrome, spina bifid, and gastroschisis within a 4-
month period, 1 month before and 3 months after conception [63]. In addition, the
use of it in the first trimester may reduce fetal heart rate from non-teratogenic
effects [64]. Use of morphine late in pregnancy may result in decreased fetal
breathing movements or withdrawal signs in the newborn [65, 66]. Withdrawal
signs are hypothermia, hyperthermia, diarrhea, vomiting, anorexia, weight gain,
high-pitched crying, hyperactivity, increased muscle tone, increased wakefulness,
abnormal sleep pattern, irritability, sneezing, seizure, tremor, yawning and etc.
[67, 68].
Effects on lactation: Both morphine and an active metabolite, M6G, can be
detected in breast milk [69]. According to previous study, a milk:plasma ratio of
morphine was 2.85, and the estimated maximum concentration in milk was
500 ng/mL [70]. Respiratory depression or drowsiness were not common in infants
of breastfeeding mothers receiving morphine [71]. Although not preferred in lacta-
tion, it should be used as soon as possible and at the lowest dose if necessary [72].
2.2 Noscapine
IUPAC name: (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-
5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one.
ATC
Code
R-
Respiratory
system
R05-Cough and
cold
preparations
R05D-Cough suppressants,
excl. combinations with
expectorants
R05DA-Opium
alkaloids and
derivatives
R05DA07-
Noscapine
Noscapine, also known as narcotine, is the second opioid alkaloid according to
its density in raw Papaver somniferum L. plant, was first isolated by Robiquet in 1817
[73]. Noscapine has no morphine-like effect, no affect on morphine withdrawal and
has mild analgesic effect [74]. It is used to suppress cough frequency and intensity
in bronchial asthma and pulmonary emphysema as it has central antitussive activity
such as codeine [74, 75]. It is thought that noscapine exerts its antitussive effect
through σ receptor which is one of the other opioid receptors. Repeated exposure to
noscapine does not lead to dependence and tolerance to its antitussive effect does
not develop. The potential for antineoplastic treatment is being investigated
because of its antimitotic effect [76]. In the animal study, noscapine increased
histamine release, leading to bronchoconstruction and hypotension, even convul-
sions [77]. There are also studies showing that teratogen [78]. Noscapine is used
orally in the form of a combined preparation to reduce these effects.
Noscapine in terms of antitussive potency, onset, and duration of action is
similar to codeine, one of the main opium alkaloids [74]. Noscapine has a relatively
low bioavailability due to a first-pass metabolism [79]. Noscapine is inactivated by
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converting into meconin and o-demethylated metabolites. Meconin is major urinary
metabolite of noscapine [80].
Adverse reactions are not expected when used in therapeutic doses [74]. When
taken in high doses, drowsiness, headache, nausea, vasomotor rhinitis, conjunctivi-
tis may be seen [81].
Effects on reproduction and pregnancy is unknown.
Effects on lactation: It is thought to have no negative effects on infant [82].
2.3 Codeine
IUPAC Name: (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-
hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol
ATC
Code
R-Respiratory
system
R05-Cough
and cold
preparations
R05D-Cough suppressants,
excl. combinations with
expectorants
R05DA-Opium
alkaloids and
derivatives
R05DA04-
Codeine
Codeine, a 3-methylether derivative of morphine, is the third opioid alkaloid
according to its density in the raw Papaver somniferum L. plant, was first isolated by
Robiquet in 1833. Codeine and its metabolite, morphine, act by stimulating opioid
receptors. The main effects are analgesia (lighter than morphine), central antitus-
sive and antidiarrheal effects [83]. It can also do sedation, drowsiness, and respira-
tory depression. Codeine is used in the management of mild to moderate pain, in
the treatment of cough, persistent diarrhea and restless leg syndrome. Codeine is
taken orally and intramuscularly.
Absorption is rapidly in oral use and bioavailability is higher due to less first-pass
metabolism (about 53%). Codeine is distributed to a variety of tissues, with priority
being to the liver, spleen and kidney [84]. Codeine-6-glucuronide, morphine, and
norcodeine is formed as a result of hepatic metabolism. Morphine is then metabo-
lized to M3G and M6G, and contributes to analgesic effects of codeine. The half-life
elimination is about 3 h and excretion is mostly done through urine and with less
feces.
In adults 7–14 mg/kg, in children more than 5 mg/kg intake leads to death [85].
Codeine blood concentration within 20–50 μg/dL is toxically, if it is above 60 μg/dL
is lethally [86].
Abnormal dreams, insomnia, depression, paresthesia, agitation, anxiety, ataxia,
dizziness, disorientation, sedation, euphoria, fatigue, hallucination, headache, bra-
dycardia, tachycardia, circulatory depression, flushing, pruritus, skin rash, urti-
caria, bronchospasm, dyspnea, respiratory depression, abdominal cramps, anorexia,
constipation, diarrhea, nausea, urinary hesitancy, urinary retention, blurred vision,
diplopia, miosis, nystagmus, laryngospasm, muscle rigidity, tremor, hypogonadism,
etc. may occur due to codeine use.
Contraindications are hypersensitivity to codeine, pediatric patients <12 years
of age, postoperative management in pediatric patients <18 years of age who have
undergone tonsillectomy and/or adenoidectomy, significant respiratory depression,
acute or severe bronchial asthma in the absence of resuscitative equipment, GI
obstruction.
Effects on reproduction: Prolonged codeine use can cause secondary
hypogonadism, which can lead to infertility in both sexes [62].
Effects on pregnancy: It is known that, codeine crosses the placenta. The use in the
first trimester can lead to respiratory tract malformation, pyloric stenosis, inguinal
hernia, neural tube defects, cardiac and circulatory system defects, and cleft lip and
palate [63, 87]. The use of codeine late in pregnancy may result in neonatal
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withdrawal syndrome, characterized by tremor, jitteriness, diarrhea, and poor
feding [88].
Effects on lactation: Both codeine and an active metabolite, morphine, can be
detected in breast milk [89]. A milk: plasma ratio of codeine is unknown. Respira-
tory depression, sedation and withdrawal signs can be seen in infants of
breastfeeding mothers receiving codeine [90].
2.4 Thebaine
IUPAC Name: (4R,7aR,12bS)-7,9-dimethoxy-3-methyl-2,4,7a,13-tetrahydro-
1H-4,12-methanobenzofuro[3,2-e]isoquinoline.
Thebaine, also known as paramorphine, which is not used for medicinal
purposes and is used for the production of other opioids, is the fourth opioid
alkaloid according to its density in the raw Papaver somniferum L. plant. Thebaine
exposure can be addictive as in the use of morphine, as well as strychnine-like
convulsions [91].
2.5 Papaverine
IUPAC name: 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline
ATC
Code
A-Alimentary
tract and
metabolism
A03-Drugs for
functional
gastrointestinal
disorders
A03A-Drugs for
functional
gastrointestinal
disorders
A03AD-
Papaverine and
derivatives
A03AD01-
Papaverine
G-Genito urinary
system and sex
hormones
G04-Urologicals G04B-Urologicals G04BE-Drugs
used in erectile
dysfunction
G04BE02-
Papaverine
Papaverine, which has no opioid-like effect, is the fifth opioid alkaloid based on
its density in the raw Papaver somniferum L. plant, first isolated from opium by
Merck in 1848. Papaverine affects the heart muscle and vascular smooth muscle by
blocking non-selective phosphodiesterase and calcium channels [92]. Papaverine
suppresses conduction and prolongs the refractory period in the heart. Vasodilata-
tion occurs with direct effect on vascular smooth muscles including coronary and
pulmonary arteries. Papaverine-mediated relaxation in smooth muscles is indepen-
dent of muscle innervation and therefore does not cause paralysis in the muscles.
Papaverine-mediated these effects are more pronounced especially in ischemia with
arteriospasm [93]. Papaverine is used in the treatment of myocardial infarction,
angina, peripheral and pulmonary embolism, peripheral vascular disease, cerebral
angiospastic states. It can also be used in hypertension, urinary incontinence, pros-
tate hyperplasia and erectile dysfunction [94]. Papaverine also has antiviral activity,
which is particularly pronounced against respiratory syncytial virus, cytomegalovi-
rus and HIV [95]. Papaverine is taken orally, intramuscularly, intravenously, and
intra-arterially.
Absorption is nearly total in oral use. Oral bioavailability is higher due to less
first-pass metabolism (about 54%). Papaverine is distributed to a variety of tissues,
with priority being to the adipose tissue and liver. 6-Desmethylpapaverine (6-DMP,
major metabolite) and 40,6-didesmethylpapaverine (4,6-DDMP) is formed as a
result of hepatic metabolism [96]. Half-life elimination is 0.5–2 h. The excretion of
papaverine is through primarily urine [97]. No information on toxic blood concen-
trations is available. The oral median lethal dose in rats is 360 mg/kg, unknown in
humans [98].
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Adverse reactions are flushing, hypertension, tachycardia, headache, malaise,
sedation, abdominal distress, anorexia, constipation, etc.
Use in the complete AV block is contraindicated.
Effects on reproduction and lactation is unknown.
Effects on pregnancy: It is not considered to have a adverse effect on infants.
3. Conclusions
Although information about opium alkaloids was about 3000 BC, it was first
isolated in the 1800s. Opioid-like effects occur after opioid alkaloids bind to con-
ventional opioid receptors, such as μ, δ, and κ. In particular, as a result of the
agonistic effect on μ receptors, strong analgesia, physical dependence, tolerance and
increased dopaminergic activity develop in the mesocorticolimbic system responsi-
ble for dependence. Increased dopaminergic activity in the mesocorticolimbic sys-
tem, is a sign of developing physical dependence, decreases in the absence of opium
alkaloids, leading to withdrawal syndrome. Hypogonadism in opium alkaloids users
supports the idea that it has a suppressive effect on reproduction. In addition to the
risk of teratogenicity, use in both pregnancy and lactation may lead to the develop-
ment of abstinence syndrome in infants.
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